Product Information
LUBIPROSTONE 8 MCG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.6039 per EA under NDC 00480347906. Its NADAC has been published 175 times since Feb 22, 2023.
Strength
8 ug/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480347906
Classification
Generic
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LUBIPROSTONEApproval Type
Generic (ANDA)
FDA Application
ANDA209920On Market Since
1/3/2023
Pharmacological Classes
Price Statistics
The NADAC for LUBIPROSTONE 8 MCG CAPSULE has been published 175 times since Feb 22, 2023, and over the history we have for it it has declined 86.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6039 per EA |
|---|---|
| All-time high | $4.3426 (Mar 15, 2023) |
| All-time low | $0.5447 (Nov 20, 2024) |
| 52-week high | $0.8921 |
| 52-week low | $0.6039 |
| Median price | $0.8194 |
| Average price | $1.1319 |
| Largest weekly change | -46.8% (Dec 20, 2023) |
| Weeks tracked | 175 |
| Tracking since | Feb 22, 2023 |
Generic Alternatives
The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of LUBIPROSTONE 8 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 8 MCG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.6039 per EA (NDC 00480347906), effective Jun 24, 2026.
How has the price of LUBIPROSTONE 8 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has declined 86.1%. It has been tracked across 175 weekly CMS publications since Feb 22, 2023.
What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 8 MCG CAPSULE?
Since Feb 22, 2023, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has ranged from a low of $0.5447 (Nov 20, 2024) to a high of $4.3426 (Mar 15, 2023), with a median of $0.8194 per EA.
Are there cheaper alternatives to LUBIPROSTONE 8 MCG CAPSULE?
3 NADAC-published products share the same active ingredient, strength, and dosage form as LUBIPROSTONE 8 MCG CAPSULE, but none are currently priced below it.
Who manufactures LUBIPROSTONE 8 MCG CAPSULE?
LUBIPROSTONE 8 MCG CAPSULE (NDC 00480347906) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification